Biovista Personalized Medicine and Diginova to deliver next generation AI-driven doctor/patient support

Deal brings broad-spectrum healthcare AI to over a quarter of a billion patients

  

CHARLOTTESVILLE, Va. and DUBAI, UAE, Sept. 15, 2021 /PRNewswire/ -- Biovista Personalized Medicine and Diginova Health Solutions today announced their deal to deliver augmented intelligence (AI)-driven personalized medicine analytics to over a quarter of a billion patients in Asia, starting in the MENA region. Diginova will offer Biovista Personalized Medicine's market-leading AI Health ShieldTM analytics direct-to-consumer, where the consumers are doctors, patients, their family caregivers, and national/regional health systems.  

"We are excited to partner with Diginova on bringing our AI Health ShieldTM to a major part of the world," said Aris Persidis, Biovista Personalized Medicine's Managing Director. "Diginova is excellent at integrating the right health solutions for patients and doctors and has an innovation-led vision for the future of healthcare that is aligned with ours," he continued.

"Outside of cancer, there were no AI-based solutions that could deeply understand patient data, including the use of data to understand existing therapies versus unanticipated ones, until the arrival of Biovista Personalized Medicine's AI Health ShieldTM," said Sarper Tanli, CEO of Diginova. "Biovista Personalized Medicine helps us deliver high quality-analytics to our consumers for any real-world clinical scenarios they may be facing. We see the AI Health ShieldTM as a real disruptor in the delivery of data-driven healthcare services," he added.

"We see this deal as generating potentially over $5 billion in new AI-driven service revenues over its current iteration and lifetime," said Persidis, "helping us continue to engineer better healthcare for everybody's future," he added.

About Biovista Personalized Medicine's AI Health ShieldTM:  It compares a patient's current diagnosis and treatment program against the many millions of evidence-based research reports published annually in scientific journals. It then recommends either extensions or replacements of the standard of care when the latter fails. Such augmented intelligence-supported analytics help physicians to adjust treatment plans and medications as well as pro-actively "think differently" for patients in need. Going beyond AI-based systems focused primarily in cancer as offered by competing personalized medicine companies, Biovista Personalized Medicine's AI Health ShieldTM was designed from the start to be disease/therapy agnostic.

About Biovista Personalized Medicine: The company is a wholly-owned subsidiary of Biovista, Inc., the award-winning pioneer in AI-driven drug repositioning and personalized medicine. Biovista Personalized Medicine's focus is the delivery of the class-leading AI-Health ShieldTM to consumers, patients, caregivers, doctors and health systems.

About Diginova: Based in the UAE, Diginova advances evidence-based technologies and digital care models to treat a broad spectrum of conditions, both chronic and otherwise. Diginova's multi-functional digital health platforms include, but are not limited to therapeutic care, diagnostics, HCP upskilling and more.

-Ends-

Further information:
For BPM: info@biovista.com 
For Diginova: info@diginovahealth.com 

SOURCE Biovista

Website: http://www.biovista.com 

Send us your press releases to pressrelease.zawya@refinitiv.com

© Press Release 2021

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.


More From Press Releases